{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.6","upperLimit":"31.1","value":"20.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"description":"Complete remission with partial hematologic recovery is a derived response based on bone marrow blast and hematology laboratory values. CRh rate is defined as the percentage of participants who achieved CRh as the best response at any time point during the study.\n\nA participant achieved a CRh when meeting the following criteria:\n\n* Bone marrow with \\< 5% blasts and\n* Peripheral blood neutrophil count of \\> 0.5 × 10\\^3 /µL and\n* Peripheral blood platelet count of \\> 0.5 × 10\\^5 /µL and\n* A 1 week (≥ 7 days) platelet transfusion-free period prior to the hematology lab collection.\n\nParticipants who never achieved CRh or did not have disease assessment or hematology data were considered to be non-responders in the calculation of CRh rate.","dispersionType":"95% Confidence Interval","groups":[{"description":"Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 50 mg, and increased up to 600 mg by Day 6. Beginning with Cycle 2, 600 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received LDAC (20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle.\n\nParticipants could continue receiving treatment until disease progression or until discontinuation criteria were met.","id":"OG000","title":"Phase 1+2: 600 mg Venetoclax + LDAC"}],"paramType":"NUMBER","populationDescription":"All enrolled participants who received venetoclax with LDAC at the recommended Phase 2 dose (600 mg)","reportingStatus":"POSTED","timeFrame":"Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.","title":"Complete Remission With Partial Hematologic Recovery (CRh) Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}